FUJIFILM HOLDINGS AMERICA CORPORATION
ent_019fccf3bf4788feda1b8fa36d005fc2
Disclosures
1
State AG · 1 jurisdiction
Multi-filing incidents
—
no multi-filing incident in sample
Max affected reported
1
as filed · State AG MA
Leak-site claims
0
none in sample
Identity resolution
- Canonical name
- FUJIFILM HOLDINGS AMERICA CORPORATION
- Normalized
- fujifilm holdings america— dedupe via name-norm; Microsoft / MSFT collapse to one row
- GLEIF LEI
- 549300P4IE66QS3RCB92
- SEC EDGAR CIK
- None — not an SEC registrant
- Domain
- None on record
- Corporate parent
- 富士フイルムホールディングス株式会社— per GLEIF relationship records
Disclosure history (1)newest first
Subsidiary disclosures (6)filed by group companies
◈ These filings were made by or about subsidiaries of FUJIFILM HOLDINGS AMERICA CORPORATION — not by FUJIFILM HOLDINGS AMERICA CORPORATION itself. Corporate relationships are mapped from GLEIF relationship records and SEC Exhibit 21 filings.
- GLOBALLeak Sitevia Fujifilm2025-08-17
Fujifilm is a globally recognized Japanese multinational corporation known for its innovative contributions to the photography and imaging industry. Founded in 1934, Fujifilm's portfolio now includes products and services in fields such as medical imaging, graphic arts, optical devices, and data storage. With decades of research and technological advancement, the firm continues to influence photography and other industries worldwide.
- GLOBALLeak Sitevia Fujifilm2025-04-05
Fujifilm has actively promoted the research and development of liposome formulations by harnessing its advanced nano-dispersion technology, analysis technology, and process technology cultivated and evolved through its wide range of product development. In 2017, the company began a U.S. Phase I clinical trial of FF-10832, a liposome-based agent that encapsulates the approved anti-cancer agent gemcitabine *** . In the preclinical mice studies on FF-10850 and FF-10832 *4 Fujifilm has observed the extension of the survival period as a result of immune checkpoint inhibitor *5 combination therapy. In addition, Fujifilm has been promoting the application of liposome for use with next-generation drugs such as nucleic acid drugs and gene therapy drugs. Looking towards future growth, in order to ensure a stable supply of high-quality liposome formulations, Fujifilm is developing a manufacturing facility for producing investigational and commercial drugs through its subsidiary, FUJIFILM Toyama.Geo: Singapore - Leak size: NO DATA 1 pdf - Contains: NO DATA 1 pdf
- New Hampshire State AGvia Fujifilm2021-06-16
FUJIFILM Dimatix, Inc. notified the NH Attorney General of a data breach involving a former employee. On June 3, 2021, the former employee emailed a Medicare-related form containing personal and employment information from her personal email account to FDMX. FDMX returned the completed form. The employee later reported not receiving it, and FDMX received suspicious emails from a similar address, suggesting the employee's personal email was compromised. The incident affected one individual. FDMX recommended the individual file a police report, secure accounts, and place a fraud alert.
- GLOBALLeak Sitevia Fujifilm2021-06-01
- Massachusetts State AGvia Fujifilm2012-09-24
Fujifilm reported a data breach to the Massachusetts Office of Consumer Affairs and Business Regulation. The breach was reported on 2012-09-24. 5 Massachusetts residents were affected. The report records the breach type as electronic.
- New Hampshire State AGvia Fujifilm2012-09-17
Fujifilm Recording Media U.S.A., Inc. notified the NH Attorney General of unauthorized access to an employee's email account on August 13, 2012. An unknown individual used the account to attempt fraud against Fujifilm. The investigation revealed that one New Hampshire resident's Social Security Number and financial information (from a 1099 report) was contained in the employee's email files. Fujifilm hired forensic investigators, reported the incident to law enforcement, and offered one year of credit monitoring to the affected individual.